AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cardiac rehabilitation program (rehab care)
Number of subjects: 180
Study 3551088 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital rehabilitation (usual care)
Number of subjects: 180
Study 29301555 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTimal nutrition by Informing and Capacitating FMs of best practices (OPTICs)
Number of subjects: 150
Study 29301555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU Workbook (web-based decision-support intervention)
Number of subjects: 150
Study 29301555 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 27209611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) composite grafts
Number of subjects: 363
Study 27209611 — intervention group
Group type: COMPARATOR
Intervention: Total arterial (TA) composite grafts
Number of subjects: 363
Study 27209611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) composite grafts (propensity score-matched)
Number of subjects: 363
Study 27209611 — intervention group
Group type: COMPARATOR
Intervention: Total arterial (TA) composite grafts (propensity score-matched)
Number of subjects: 363
Study 27209611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (both groups)
Number of subjects: 363
Study 27209611 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from major adverse cardiac and cerebrovascular events (both groups)
Number of subjects: 363
Study 26232137 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 oz. 100% berry fruit juice
Number of subjects: 26
Study 26232137 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 oz. water
Number of subjects: 26
Study 26232137 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fruit juice
Number of subjects: 26
Study 22658845 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured orthosis
Number of subjects: 12
Study 22658845 — intervention group
Group type: COMPARATOR
Intervention: Flat insert
Number of subjects: 12
Study 21795458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Number of subjects: 66
Study 21795458 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Number of subjects: 66
Study 21795458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Number of subjects: 66
Study 21795458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) and 2 doses of PV
Number of subjects: 66
Study 19464414 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime
Number of subjects: 120
Study 16945877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment scales (intervention group)
Number of subjects: 772
Study 16945877 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 772
Study 15265241 — intervention group
Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily for 5, 7, or 10 days
Number of subjects: 1023
Study 15265241 — intervention group
Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily for 7-10 days
Number of subjects: 1023
Study 15265241 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily for 10 days
Number of subjects: 1023
Study 11764434 — intervention group
Group type: EXPERIMENTAL
Intervention: Futura-type wrist splint
Number of subjects: 201
Study 11764434 — intervention group
Group type: COMPARATOR
Intervention: Traditional forearm plaster-of-Paris cast
Number of subjects: 201
Study 10090696 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8033435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 0
Study 8033435 — intervention group
Group type: COMPARATOR
Intervention: Control treatments (anti-cholinesterase drugs, thymectomy, corticosteroids, immunosuppressants, plasma exchange)
Number of subjects: 0
Study 2645845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention in place of antihypertensive drugs
Number of subjects: 0
Study 2645845 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 0
Study 2645845 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring, echocardiography, roentgenography, and electrocardiography
Number of subjects: 0
Study 28397962 — intervention group
Group type: EXPERIMENTAL
Intervention: General explanations in biology
Number of subjects: 149
Study 28397962 — intervention group
Group type: EXPERIMENTAL
Intervention: General explanations in physics
Number of subjects: 149
Study 27538003 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHA (+) with integral 0.3% lidocaine
Number of subjects: 102
Study 27538003 — intervention group
Group type: COMPARATOR
Intervention: CaHA without lidocaine
Number of subjects: 102
Study 24640268 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml dexamethasone/bupivacaine/gentamicin (DMG) solution
Number of subjects: 20
Study 24640268 — intervention group
Group type: COMPARATOR
Intervention: 100 ml saline solution
Number of subjects: 20
Study 21873895 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-on formula supplemented with Lactobacillus fermentum CECT5716 plus galactooligosaccharide (EG)
Number of subjects: 100
Study 20690094 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and intensive statin therapy (60 mg immediately and 40 mg/day atorvastatin)
Number of subjects: 586
Study 20690094 — intervention group
Group type: COMPARATOR
Intervention: Conventional statin therapy (10 mg/day atorvastatin)
Number of subjects: 586
Study 18646702 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (Capecitabine plus Oxaliplatin)
Number of subjects: 256
Study 18646702 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX4
Number of subjects: 256
Study 18646702 — intervention group
Group type: COMPARATOR
Intervention: de Gramont regimen
Number of subjects: 256
Study 16167963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (50 IU)
Number of subjects: 572
Study 16167963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water in 25 mL saline)
Number of subjects: 572
Study 12876178 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human secretin 2 U/kg
Number of subjects: 62
Study 12876178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 62
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR with tyrosinase
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR with MART‐1
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: MART‐1-positive CMCs
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosinase-positive CMCs
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosinase and MART‐1 expression
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosinase-positive but MART‐1-negative CMCs
Number of subjects: 186
Study 10561323 — intervention group
Group type: EXPERIMENTAL
Intervention: MART‐1 and tyrosinase PCR
Number of subjects: 186
Study 2091361 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-containing glucose electrolyte solution (GES)
Number of subjects: 115
Study 2091361 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize-salt solution (MSS)
Number of subjects: 115
Study 381074 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercialized anatoxin (30 Lf per dose, adsorbed on Ca phosphate)
Number of subjects: 595
Study 381074 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercialized anatoxin (30 Lf per dose, adsorbed on Al hydroxide)
Number of subjects: 595
Study 381074 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental anatoxin (25 Lf per dose, adsorbed on Al phosphate)
Number of subjects: 595
Study 381074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study 31035187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for 120 h)
Number of subjects: 20
Study 31035187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study 31035187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 20
Study 28450262 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using diode laser 660 nm mediated by methylene blue (MB)
Number of subjects: 20
Study 28450262 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (kenakort A-orabase)
Number of subjects: 20
Study 26374203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month Tobacco Status Project intervention on Facebook
Number of subjects: 0
Study 26374203 — intervention group
Group type: COMPARATOR
Intervention: Referral to a smoking cessation website
Number of subjects: 0
Study 24293994 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (bilevel positive airway pressure, 15/5 cm H2O)
Number of subjects: 30
Study 24293994 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 30
Study 21133980 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB+β‐TCP
Number of subjects: 54
Study 21133980 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP
Number of subjects: 54
Study 19958541 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (treatment group)
Number of subjects: 0
Study 19958541 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 0
Study 17310937 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cognitive counseling (PCC)
Number of subjects: 336
Study 17310937 — intervention group
Group type: COMPARATOR
Intervention: Usual counseling (UC)
Number of subjects: 336
Study 15026904 — intervention group
Group type: EXPERIMENTAL
Intervention: One proximal endoloop (group 1)
Number of subjects: 208
Study 15026904 — intervention group
Group type: COMPARATOR
Intervention: Two proximal endoloops (group 2)
Number of subjects: 208
Study 11777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenous single dose followed by oral cefixime
Number of subjects: 144
Study 11777865 — intervention group
Group type: COMPARATOR
Intervention: Daily intravenous dose of 1 g ceftriaxone
Number of subjects: 144
Study 9693354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal replacement therapy
Number of subjects: 105
Study 9693354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential hormonal replacement therapy
Number of subjects: 105
Study 9693354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8081181 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 12
Study 8081181 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide
Number of subjects: 12
Study 8081181 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% nitrous oxide
Number of subjects: 12
Study 8081181 — intervention group
Group type: COMPARATOR
Intervention: 0% (oxygen-placebo)
Number of subjects: 12
Study 2723991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric surgical service (P-Surg)
Number of subjects: 139
Study 2723991 — intervention group
Group type: COMPARATOR
Intervention: Adult surgical services (G-Surg)
Number of subjects: 139
Study 394303 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 52
Study 394303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine
Number of subjects: 52
Study 394303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31416489 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (translated Wellbeing Course)
Number of subjects: 63
Study 31416489 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 63
Study 31007103 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous curved vertebroplasty (PCVP)
Number of subjects: 78
Study 31007103 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral percutaneous vertebroplasty (PVP)
Number of subjects: 78
Study 31007103 — intervention group
Group type: COMPARATOR
Intervention: Bilateral percutaneous vertebroplasty (PVP)
Number of subjects: 78
Study 28583145 — intervention group
Group type: EXPERIMENTAL
Intervention: De Qi group (enhanced stimulation to evoke De Qi)
Number of subjects: 88
Study 28583145 — intervention group
Group type: COMPARATOR
Intervention: Control group (weak stimulation to avoid De Qi)
Number of subjects: 88
Study 28583145 — intervention group
Group type: EXPERIMENTAL
Intervention: De Qi group
Number of subjects: 88
Study 28583145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 28583145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 26453554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus clinical reminder system (TC)
Number of subjects: 26
Study 26453554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus clinical reminder system plus referral to a village health worker (TCR)
Number of subjects: 26
Study 24120756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia visual perceptual group training
Number of subjects: 64
Study 24120756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia visual perceptual individual training
Number of subjects: 64
Study 24120756 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper visual perceptual group training
Number of subjects: 64
Study 24120756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 64
Study 23010962 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight at 1 year
Number of subjects: 123
Study 23010962 — intervention group
Group type: EXPERIMENTAL
Intervention: αCa (calcium absorption)
Number of subjects: 123
Study 23010962 — intervention group
Group type: COMPARATOR
Intervention: Birth weight
Number of subjects: 123
Study 19858706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 302
Study 19858706 — intervention group
Group type: COMPARATOR
Intervention: Hernia repair
Number of subjects: 302
Study 18241560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 42
Study 18241560 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 42
Study 18241560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HALS and OS
Number of subjects: 42
Study 16162254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 250 mg acetylsalicylic acid + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Number of subjects: 1743
Study 16162254 — intervention group
Group type: COMPARATOR
Intervention: All active treatments except caffeine
Number of subjects: 1743
Study 12355200 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHS
Number of subjects: 14
Study 12355200 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% CHS
Number of subjects: 14
Study 12355200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10439763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg as a 5‐mL i.v. injection 5 min before surgery
Number of subjects: 128
Study 10439763 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 5 mL i.v. at the time of skin closure
Number of subjects: 128
Study 10439763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg i.v. at the time of skin closure
Number of subjects: 128
Study 8574255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose if needed)
Number of subjects: 1108
Study 8574255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 600 micrograms (2nd dose)
Number of subjects: 1108
Study 8574255 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose)
Number of subjects: 1108
Study 8574255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose)
Number of subjects: 1108
Study 8574255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol
Number of subjects: 1108
Study 2229278 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms sc every 8 h, increased to 200 micrograms)
Number of subjects: 20
Study 2229278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2229278 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 20
Study 7446925 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal intradural analgesia
Number of subjects: 150
Study 7446925 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with spontaneous ventilation (Group B)
Number of subjects: 150
Study 7446925 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with controlled ventilation (Group C)
Number of subjects: 150
Study 31926846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 3
Study 30559055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane seeded with fetal fibroblasts (AM-F group)
Number of subjects: 10
Study 30559055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM group)
Number of subjects: 10
Study 30559055 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze (control group)
Number of subjects: 10
Study 28963455 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 118
Study 28963455 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 118
Study 25463456 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorization of a complex artificial pattern followed by mental rotation of the image as instructed by a cue.
Number of subjects: 0
Study 23732073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensor tenotomy with tensor tenopexy (n=9)
Number of subjects: 17
Study 23732073 — intervention group
Group type: COMPARATOR
Intervention: Tensor tenotomy (n=8)
Number of subjects: 17
Study 21385401 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature; daily qualitative symptom questionnaire; routine telephone contacts every fortnight)
Number of subjects: 60
Study 21385401 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 60
Study 21385401 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 19710679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine
Number of subjects: 60
Study 19710679 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 60
Study 19710679 — intervention group
Group type: COMPARATOR
Intervention: No skin cleansing
Number of subjects: 60
Study 17261216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pretreatment of remifentanil (0.35 microg kg(‐1) min(‐1)) and premixture of lidocaine with propofol (1% propofol and 1% lidocaine in a 10:1 ratio)
Number of subjects: 141
Study 17261216 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil pretreatment (0.35 microg kg(‐1) min(‐1))
Number of subjects: 141
Study 17261216 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine premixture with propofol
Number of subjects: 141
Study 17261216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (remifentanil and lidocaine)
Number of subjects: 141
Study 14871466 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF-alpha humanized antibodies (infliximab)
Number of subjects: 98
Study 14871466 — intervention group
Group type: COMPARATOR
Intervention: soluble cytokine
Number of subjects: 98
Study 14871466 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 98
Study 11728350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 0
Study 11728350 — intervention group
Group type: COMPARATOR
Intervention: tissue plasminogen activator (t-PA)
Number of subjects: 0
Study 9210852 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults performing lexical tasks
Number of subjects: 0
Study 9210852 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lexical decision and category judgment tasks
Number of subjects: 0
Study 9210852 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming effects
Number of subjects: 0
Study 9210852 — intervention group
Group type: EXPERIMENTAL
Intervention: All old subgroups (fast, medium, slow)
Number of subjects: 0
Study 7970234 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 allele frequency in Lewy body dementia (LBD)
Number of subjects: 154
Study 7970234 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 allele frequency in Alzheimer's disease (AD)
Number of subjects: 154
Study 7970234 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-demented)
Number of subjects: 154
Study 3115846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate transdermal patch (10 mg daily)
Number of subjects: 40
Study 3115846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30946269 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest running (WVR) with 10% body mass (BM)
Number of subjects: 17
Study 30946269 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest running (WVR) with 5% body mass (BM)
Number of subjects: 17
Study 30946269 — intervention group
Group type: COMPARATOR
Intervention: Control (no vest)
Number of subjects: 17
Study 31170299 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 96
Study 31170299 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 96